Zacks Bull and Bear of the Day Highlights: Red Robin Gourmet Burgers, hhgregg, Actavis, AstraZeneca and Mylan
CHICAGO, March 4, 2013 /PRNewswire/ -- Zacks Equity Research highlights Red Robin Gourmet Burgers (Nasdaq: RRGB) as the Bull of the Day and hhgregg (NYSE: HGG) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Actavis, Inc. (NYSE: ACT), AstraZeneca (NYSE: AZN) and Mylan (Nasdaq: MYL).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Many investors were worried that the Fiscal Cliff deal would be devastating to consumer discretionary firms. The prospect of higher taxes was expected to cut into many paychecks, and curtail spending levels in the process.
This has not been the case through the first two months of the year though, as many consumer discretionary firms, and particularly several in the restaurant space, have seen great starts to 2013. This has especially been the case for the small but surging Red Robin Gourmet Burgers (Nasdaq: RRGB).
If you haven't heard of Red Robin, don't be worried. The firm isn't exactly McDonald'sor even Wendy's in terms of its scope, as the Colorado-based company has less than 500 total restaurants. Still, the number of Red Robin locations is quickly surging as many consumers are embracing their lineup of burgers and various other lunch and dinner items.
Electronic retailing was once a lucrative business. Companies like Best Buyand RadioShackdominated the field and were known across the country by anyone looking for a TV, videogame, or computer.
However, with the rise of Amazonand other e-commerce sites, many of these electronic retailers have become merely showrooms for online firms. This has allowed internet companies to poach sales from big box stores, and crater profits for brick-and-mortar companies that are drowning under high fixed costs.
While most investors have focused in on the giants of the space, some relative newcomers, like hhgregg (NYSE: HGG), have also been impacted by the trends. In fact, the small electronic retailer has seen its share price tumble by about one-third in the past two years.
This is obviously a pretty depressing trend given that the broad market has been well into the green in the time period. However, it is worth noting that the stock hasn't been going straight down, as HGG has added about 30% in the year-to-date time frame.
Latest Posts on the Zacks Analyst Blog:
FDA Approves Actavis Generic
Actavis, Inc. (NYSE: ACT) recently gained US Food and Drug Administration (FDA) approval for its generic version of Suboxone (buprenorphine HCl and naloxone HCl dihydrate SL tablets, 2 mg/0.5 mg and 8 mg/2 mg).
The company intends to launch its generic version of Suboxone immediately. Suboxone, which is indicated for the maintenance treatment of opioid dependence, posted sales of about $625 million in the US for the 12 months ending Dec 31, 2012. The sales data is as per IMS Health.
Actavis Pharma, the company's global generics business, is expected to post revenues of $6.3 billion - $6.5 billion in 2013. The segment had posted sales of $4.4 billion in 2012, up 32%.
Actavis is the third largest player in the global generics market and has a presence in more than 60 countries. As of Dec 31, 2012, Actavis had more than 185 Abbreviated New Drug Applications (ANDAs) pending FDA approval. These include 49 first-to-file opportunities of which 33 could be exclusive first-to-files.The company intends to launch its generic version of AstraZeneca's (NYSE: AZN) Pulmicort Respules in the second quarter of 2013. While Actavis expects an additional competitor for generic Concerta to enter the market in the first quarter of 2013 and a second competitor later this year, it does not expect any competition for its generic versions of Lidoderm and Adderall XR until 2014.
Actavis currently carries a Zacks Rank #3 (Hold). Other generic players like Mylan (Nasdaq: MYL) currently look better positioned with a Zacks Rank #2 (Buy).
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.